Analysis of BRAF and NRAS mutation status in advanced melanoma patients treated with anti-CTLA-4 antibodies: Association with overall survival?
Joanna Mangana
Honoraria - LA ROCHE POSAY
Simone M. Goldinger
No relevant relationships to disclose
Katja Schindler
Honoraria - Bristol-Myers Squibb
Sima Rozati
Employment or Leadership Position - Research Fellow
Anna L. Frauchiger
No relevant relationships to disclose
Markus Rechsteiner
Research Funding - Roche
Holger Moch
Research Funding - Roche
Emanuela Romano
Honoraria - Bristol-Myers Squibb
Katharina C. Kaehler
Honoraria - Bristol-Myers Squibb
Olivier Michielin
No relevant relationships to disclose
Axel Hauschild
Consultant or Advisory Role - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Honoraria - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Research Funding - Amgen; AstraZeneca; Boehringer Ingelheim; Bristol-Myers Squibb; Celgene; Eisai; GlaxoSmithKline; IGEA; Lilly; MELA Sciences; Merck Serono; MSD; Novartis; OncoSec; Roche
Christoph Hoeller
Consultant or Advisory Role - Bristol-Myers Squibb
Honoraria - Bristol-Myers Squibb
Reinhard Dummer
Consultant or Advisory Role - Bristol-Myers Squibb; Novartis; Roche
Honoraria - Bristol-Myers Squibb; MSD; Novartis; Roche
Research Funding - Bristol-Myers Squibb; Roche